On June 11, the official website of the National Medical Products Administration (NMPA) showed that Longcome Technology’s Lanokopan tablets (MY008211A, brand name: Yishining) have been approved for marketing for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitor therapy. This drug is the first domestically developed complement factor B (CFB) inhibitor to be approved for marketing.
Longcome Technology conducted three Phase III clinical trials for Lanokopan in the treatment of PNH.
PNH is a rare and life-threatening complement system-mediated hemolytic disease. Currently, a total of 7 drugs are approved globally for the treatment of PNH. The other 6 include eculizumab (AstraZeneca), ravulizumab (AstraZeneca), pegcetacoplan (Apellis), iptacopan (Novartis), danicopan (AstraZeneca), and crovalimab (Roche).